Definium Therapeutics, Inc. Common Shares
IPODefinium Therapeutics (Formerly MindMed) | Psychedelic Medicine
Public · New York, United States · Founded 2019 · $371.0M raised
- Headquarters
- New York, New York
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- definiumtx.com
- Total Funding
- $371.0M
- Last Round
- $225.0M Corporate RoundAug 2023
- Rounds
- 4
- Type
- Public
About
Definium Therapeutics (formerly MindMed, founded in 2019) is a clinical-stage biopharmaceutical company headquartered in New York developing psychedelic-inspired medicines for psychiatric and neurological disorders. Its lead candidate, DT120 ODT, has received FDA Breakthrough Therapy Designation for generalized anxiety disorder and is in Phase 3 trials for both GAD and major depressive disorder. The company rebranded from MindMed to Definium Therapeutics in January 2026.
Summary
Definium Therapeutics, Inc. Common Shares is a Biotech company based in New York, United States, founded in 2019. It has raised $371.0M in total across 4 rounds, most recently a $225.0M Corporate Round round in Aug 2023.
Tech & App Stack
Funding History
Aug 2023
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/definium-therapeutics-inc-common-shares"><img src="https://indexed.vc/api/badge/company/definium-therapeutics-inc-common-shares" alt="Definium Therapeutics, Inc. Common Shares on Indexed.vc" width="260" height="76" /></a>